NeOnc Technologies
NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company focused on treatments for intracranial malignancies. Its lead candidate NEO100, a purified form of perillyl alcohol delivered intranasally, is in Phase 2a development for recurrent IDH1-mutant high-grade glioma, with topline data expected in August 2026; NEO212, a covalent conjugate of temozolomide and perillyl alcohol, is in Phase 1/2 development for primary and secondary brain cancers including meningioma and glioblastoma. The company was founded by neurosurgeon-scientist Thomas C. Chen and is headquartered in Calabasas, California.
Company Info
Upcoming Milestones & Key Dates
Topline Phase 2a data readout for NEO100 in recurrent IDH1-mutant high-grade glioma
Clinical Development Pipeline
NEO100 (intranasal perillyl alcohol)
Target: Purified perillyl alcohol delivered intranasally to cross the blood-brain barrierNEO212 (temozolomide-perillyl alcohol conjugate)
Target: Covalently conjugated chemotherapeutic agentRecent News
No recent news updates available for this company.
Leadership Team
Amir Heshmatpour
President, Chief Executive Officer, Executive Chairman and Secretary
Thomas C. Chen
Founder, Chief Medical Officer, Chief Scientific Officer and Vice Chairman
Keithly A. Garnett
Chief Financial Officer